Single Center Experience of Allogeneic Peripheral Blood Stem Cell Transplantation for Acute Myeloid Leukemia.
- Author:
Woo Jin SUNG
1
;
Joon Ho MOON
;
Seok Bong JEON
;
Dong Hwan KIM
;
Jong Gwang KIM
;
Sang Kyun SOHN
;
Jang Soo SUH
;
Kun Soo LEE
;
Kyu Bo LEE
Author Information
1. Department of Hematology/Oncology, Kyungpook National University, College of Medicine, Daegu, Korea. sksohn@knu.ac.kr
- Publication Type:Original Article
- Keywords:
Allogeneic peripheral blood stem cell transplantation;
Acute myeloid leukemia;
Graft-versus-host disease;
Graft-versus-leukemic effect
- MeSH:
Blood Platelets;
Bone Marrow;
Disease-Free Survival;
Follow-Up Studies;
Graft vs Host Disease;
Granulocyte Colony-Stimulating Factor;
Granulocyte-Macrophage Colony-Stimulating Factor;
Humans;
Incidence;
Leukemia, Myeloid, Acute*;
Leukemia, Promyelocytic, Acute;
Neutrophils;
Peripheral Blood Stem Cell Transplantation*;
Siblings;
Stem Cell Transplantation;
Stem Cells;
Tissue Donors
- From:Korean Journal of Hematology
2004;39(1):16-22
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Recently, peripheral blood (PB) stem cells have been used widely for allogeneic stem cell transplantation (SCT), instead of bone marrow (BM). The current study analyzed the outcome of allogeneic PBSCT for the patients with acute myeloid leukemia (AML). METHODS: Twenty-nine patients with AML excluding AML M3 were included for the analysis. PB stem cells were collected from HLA-matched sibling donors mobilized with G-CSF with or without GM-CSF. RESULTS: Engraftment for neutrophil and platelet were achieved in a median 15.0 days and 14.0 days, respectively. The incidence of grade II~III acute graft versus host disease (GVHD) was 82.8% (24/29 patients), while of chronic GVHD 78.6% (22/28 patients, limited 11, extensive 11). During the median follow-up of 340 days (range, 86~1,603 days), 3 years overall survival and disease free survival was 51.4% and 40.0%, respectively. CONCLUSION: PB may be considered as a feasible source of allogeneic SCT for patients with AML.
